FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average b	ourden									

0.5

hours per response:

Check this box if no longer subject to	
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* WALTON ALAN G (Last) (First) (Middle) 315 POST ROAD WEST					3. D	2. Issuer Name and Ticker or Trading Symbol ACADIA PHARMACEUTICALS INC ACAD] 3. Date of Earliest Transaction (Month/Day/Year) 09/09/2005									k all appli Directo	cable) or (give title	ng Person(s) to Issu 10% Own Other (sp below)		vner	
(Street) WESTPO			06880 Zip)		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									dividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tab	le I - Non	-Deriv	ative/	Sec	curitie	s Ac	quired, [Disp	osed o	of, or Be	nefic	ially	Owned	l				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)						Execution Date,			3. Transaction Code (Instr. 8) 4. Securities Acquired (/Disposed Of (D) (Instr. 3) 5)			ed (A) o	or and	5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	V	Amount	(A) o	Pri	rice Transac (Instr. 3		tion(s)			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date,	4. Transa Code (I 8)				Expiration [. Date Exercisable an xpiration Date Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Seci (Instr. 3 and 4)		S (I	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Ow For Dir or (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A) (D)		Date Exercisable		xpiration ate	Title	Amou or Numb of Share	er						
Stock Option (Right to Buy)	\$11	09/09/2005			A		8,500		(1)	09	9/18/2015	Common Stock	8,50	00	\$0	8,500		D		

Explanation of Responses:

1. One-fourth of the shares subject to the Stock Option shall vest and become exerciseable at the end of each 3-month period following June 10, 2005.

Remarks:

/s/ Raymond Charest, as attorney-in-fact for Alan G. Walton

09/13/2005

** Signature of Reporting Person

Date

 $Reminder: Report \ on \ a \ separate \ line \ for \ each \ class \ of \ securities \ beneficially \ owned \ directly \ or \ indirectly.$

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Raymond Charest, Alexia Pearsall and Jonathan J. Fleming, and each of them, with full power to act without the other, his true and lawful attorney-in-fact and agent, with full power of substitution, for him and in his name, place and stead, in any and all capacities (until revoked in writing) to sign any and all instruments, certificates and documents required to be executed on behalf of himself as an individual or in his capacity as a general partner or authorized signatory, as the case may be, on behalf of any of Oxford Bioscience Partners $\,$ IV L.P., mRNA II L.P., or OBP Management IV L.P., pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and any and all regulations promulgated thereunder and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Exchange Act or by the By-laws of the National Association of Securities Dealers, Inc., granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary fully to all intents and purposes as he might or could do in person thereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof, or may have done in connection with the matters described above.

IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 8th day of April, 2004.

OXFORD BIOSCIENCE PARTNERS IV L.P. by its General Partner, OBP MANAGEMENT IV L.P.

By: /s/ Jonathan Fleming Name: Jonathan J. Fleming Title: General Partner

MRNA FUND II L.P. By its General Partner, OBP MANAGEMENT IV L.P.

By: /s/ Jonathan Fleming Name: Jonathan J. Fleming Title: General Partner

OBP MANAGEMENT IV L.P.

By:/s/ Jonathan Fleming Name: Jonathan J. Fleming Title: General Partner

/s/ Jeffrey T. Barnes Jeffrey T. Barnes

/s/ Mark P. Carthy Mark P. Carthy

/s/ Jonathan J. Fleming Jonathan J. Fleming

/s/ Michael E. Lytton Michael E. Lytton

/s/ Alan G. Walton Alan G. Walton